EVEXIA PRACTICE SUPPORT INFO CENTER

Welcome to the Evexia Diagnostics COVID-19 Repository Page.  Since the global health crisis concerning COVID-19 is rapidly unfolding, our focus on wellness has become increasingly vital.  As a result, we created this resource to better demonstrate our unwavering commitment to providing our clients with convenient and reliable access to insightful information, cost-effective diagnostic testing, as well as options for nutraceutical support.  On this page, you will find all matters and materials related to COVID-19, such as current updates, educational content, testing and nutraceutical recommendations.

Evexia Diagnostics remains ready to support your practice and the needs of your patients.  Please do not hesitate to contact us and let us know how we can assist you in providing the necessary support for your practice.

LATEST UPDATES

MARCH 25, 2020 - 1:30 P.M.

Evexia Diagnostics is now offering COVID-19 Testing Kits to all licensed Evexia clients. Testing is performed by our lab partner, Diagnostic Solutions Laboratory (DSL).  The DSL COVID-19 PCR test uses multiple viral targets as well as a spike protein which has been proven to improve accuracy and reduce the number of indeterminate and false negative test results.

Please be aware that quantities of the DSL Test Kits are limited and will be sold on a “first-come, first-served” basis.  The DSL COVID-19 Test Kits are available for immediate purchase in quantities of 5, 10, 15, 20, 25, or 50.

Testing Bundles include the specimen collection kit, the COVID-19 test, and expedited return shipping for clients and patients to send specimens to the lab.

Testing Bundles will NOT include the shipping charges to mail kits to individual clients or patients. These charges will be billed separately to the Evexia client account.

To order, contact our Client Success Team at (888)-852-2723. 

Evexia Diagnostics does not accept any form of insurance nor do we have the ability to seek third-party reimbursement. We are offering this test as a convenience to our clients and their patients, who may not be able or may choose not to travel to a location where the test can be charged to a third-party. The fees charged by Evexia to our clients for the COVID-19 test are a reflection of our cost related to the acquisition and distribution of the COVID-19 test and supplies. Anyone who is symptomatic and/or who meets the CDC’s guidelines for testing has the option of receiving the test for free, but they would need to locate a testing facility (clinic, drive-thru or hospital) that is able to seek 3rd-party reimbursement and have the testing done there.

MARCH 25, 2020 - 10:30 A.M.
Currently, there is a severe shortage of LabCorp COVID-19 collection kits (swabs & viral transport media), and the limited supplies available are being prioritized for hospitals and major medical centers to ensure that symptomatic patients get tested.  As a result, we have been informed by our 3rd-party supplier that there is a delay of approximately 2 or more weeks until materials will be available for the fulfillment of supply orders for the LabCorp COVID-19 collection kits.  In the meantime, we will continue to offer the LabCorp COVID-19 testing option to our clients if they can procure their own collection kits.  Please review the acceptable collection devices/kits here.


Specimen Collection Information 3.20.20 – Click Here to View

MARCH 23, 2020 - 12:00 P.M.

 

COVID-19 Testing & Patient Billing Guidance – Click Here to View

MARCH 20, 2020 - 12:00 P.M.

LabCorp PSCs (Patient Service Centers) in most locations will remain open. In addition, LabCorp will have 3 labs online performing COVID-19 testing by the end of today with the ability to handle 20,000 tests per day. This should reduce the current turnaround time, along with the Roche and Thermo Fisher technology being employed. There is currently a shortage of COVID-19 collection supplies, but this shortage is expected to be short term.

MARCH 19, 2020 - 5:00 P.M.

Media Statement: LabCorp Announces Ability to Perform 20,000 Tests Per Day, Doubles Its COVID-19 Testing Capacity in One Week

LabCorp announced that it will be able to perform more than 20,000 COVID-19 tests per day beginning Friday, March 20, ahead of its original schedule. This represents a significant increase in capacity since the company released its COVID-19 test two weeks ago. The company is working continuously to increase capacity and support the needs of healthcare workers, patients, government, clients and other organizations, and expects capacity to continue to increase.

The company is intently focused on making COVID-19 laboratory testing available to patients who are symptomatic and should be tested. LabCorp has moved quickly to significantly increase its testing capacity by adding staff, equipment and more high-throughput testing now underway as a result of approved emergency use authorization (EUAs). LabCorp is now performing COVID-19 testing at its labs in Phoenix, Ariz., Burlington, N.C., and Raritan, N.J.

As a reminder, LabCorp does not collect specimens for the test. Patients for whom testing has been ordered should not be sent to LabCorp location to have a specimen collected. Instead, an appropriate specimen must be collected at the healthcare facility where the patient was seen and the test was ordered. The specimen should be sent to the companies using standard procedures. Test results will be available in 3-4 days from the pickup of the specimen to release of the test result.


If you believe you have been exposed to Coronavirus (COVID-19), please do not enter a patient service center. Immediately contact your physician or healthcare provider. Testing must be collected by a physician or an authorized healthcare provider. LabCorp employees are not able to collect the specimens in LabCorp patient service centers.

To ensure the health of our patients, employees and the broader community, please follow these guidelines.

  1. We request the first business hour each day is set aside to serve people who are 65 or older and those with serious underlying medical conditions. 
  2. We’ve launched the “Wait Where You’re Comfortable” Program. Once checked in, you can wait in your vehicle or other nearby location. If you make an appointment online and provide your cell phone number, check in from your mobile device and we will text you when we’re ready to see you.
MARCH 18, 2020 - 11:30 A.M.

LabCorp is proud of the work that we, along with our industry partners, are doing to quickly mobilize the United States to get back on its feet by bringing access to nationwide testing for COVID-19. We continue to work closely with federal and state authorities and health officials, as well as other key constituencies to make testing available for patients who should be tested and increase test capacity in response to this public health crisis.

LabCorp does not collect specimens for COVID-19 testing at our locations, and we are asking individuals who are or may be positive for COVID-19 not to visit our locations to help minimize possible transmission. LabCorp’s patient service centers and other locations follow strict personal and environmental hygiene protocols, which have been further strengthened and reinforced with all employees since the early days of the COVID-19 outbreak. But all available evidence is that people can be contagious before exhibiting any symptoms, and without knowing that they have been exposed or may be infected.

As we learn of employees who may have been exposed, we are moving quickly to make sure they are following all recommendations and protocols, including self-quarantine, and receive appropriate care and support. We are also working in coordination with public health authorities to respond when we are informed about visitors to our locations who may have been infected and could have exposed others. If we learn of a potential exposure, the location will be closed and thoroughly cleaned so that we can bring it back online to serve patients and their healthcare needs.

The health and safety of our employees, the public, patients and healthcare service providers is of the utmost importance. We are committed to working with the relevant governmental and healthcare authorities in response to COVID-19 and ensuring that we are communicating key developments as they occur.

LabCorp and our dedicated employees are intensely focused on performing testing for COVID-19 and increasing capacity to make testing available for patients who should be tested. We are deeply proud of everything our colleagues have done to respond to this unprecedented crisis, and all that they will continue to do.

MARCH 16, 2020
Update for EDI interface customers on result reporting regarding the 2019 Novel Coronavirus (COVID‐19), NAA [139900] test – Click Here to View


Fact Sheet for Healthcare Providers – Click Here to View


Fact Sheet for Patients – Click Here to View

MARCH 13, 2020
CPT® Category I Pathology and Laboratory Code for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

Click Here To View PDF

Available Coronavirus (COVID-19) Testing

Evexia Diagnostics is offering our LICENSED clinicians the ability to collect specimens from and have testing performed on their patients for the SARS-CoV-2/COVID-19 virus. Please note, there are currently NO FDA-Approved COVID-19 tests of any kind available at this time, and all available COVID-19 testing is authorized under the FDA’s Emergency Use Authorization (EUA). For additional information from the FDA, Click Here.

The COVID-19 testing that we are offering to our clients is performed by our laboratory partners LabCorp and Diagnostic Solutions Laboratory. Both of these trusted partners are authorized under the EUA, results have been validated by independent proficiency laboratories, and the testing is performed at CLIA-Certified, High Complexity Labs, using Nucleic Acid Amplification (NAA)/Polymerase Chain Reaction (PCR) technology.

Diagnostic Solutions Laboratory (DSL)
COVID-19 Test

The DSL test includes 2 viral targets and 1 spike protein target, which was developed by DSL. All other tests in use by other labs have only 2 viral targets and are known to return indeterminate results at high rates. This is why DSL designed and built a 3 target COVID-19 test. Additionally, on any samples where a result is indeterminate, DSL will reflex to a 4th target. This approach lowers the incidence of indeterminate results even further.

Once samples are received, DSL is currently performing the COVID-19 test with a 24-hour turn-around-time.

Contact us for additional information & ordering.

888-852-2723

LabCorp 2019 Novel Coronavirus (COVID-19), Test

Currently, there is a severe shortage of LabCorp COVID-19 collection kits (swabs & viral transport media), and the limited supplies available are being prioritized for hospitals and major medical centers to ensure that symptomatic patients get tested.  As a result, we have been informed by our 3rd-party supplier that there is a delay of approximately 2 or more weeks until materials will be available for the fulfillment of supply orders for the LabCorp COVID-19 collection kits.  In the meantime, we will continue to offer the LabCorp COVID-19 testing option to our clients if they can procure their own collection kits.  Please review the acceptable collection devices/kits here.

Individuals seeking testing for COVID-19 should not visit a LabCorp location to request a test. Tests must be ordered by a physician or other authorized healthcare provider. LabCorp does not currently collect specimens for COVID-19 testing. Patients for whom testing has been ordered should not be sent to a LabCorp location to have a specimen collected.

Login to your account and use EvexiaLink to order.

Evexia Diagnostics does not accept any form of insurance nor do we have the ability to seek third-party reimbursement. We are offering this test as a convenience to our clients and their patients, who may not be able or may choose not to travel to a location where the test can be charged to a third-party. The fees charged by Evexia to our clients for the COVID-19 test are a reflection of our cost related to the acquisition and distribution of the COVID-19 test and supplies. Anyone who is symptomatic and/or who meets the CDC’s guidelines for testing has the option of receiving the test for free, but they would need to locate a testing facility (clinic, drive-thru or hospital) that is able to seek 3rd-party reimbursement and have the testing done there.

THE EVEXIA WEBINAR SERIES – SPECIAL EDITION

Wayne L. Sodano, DC, DABCI, DACBN, CFMP, CIHP, BCTN
Director of Clinical Support and Education
Evexia Diagnostics

Contributors:
Kevin K. Bodling, DC, DACBN, DABCI
President & Chief Executive Officer
Evexia Diagnostics
Will Blankenship, MD
Chief Medical Officer
Evexia Diagnostics

The underlying importance of a properly functioning immune system is highlighted as global concerns continue to grow regarding the spread of COVID-19 (Coronavirus Disease).  Evexia Diagnostics is proud to offer an educational webinar for you to learn more about the natural avenues and precautionary measures available to help safeguard against infection and to help ensure that your patient’s immune system is able to provide an adequate response to this emerging threat.

Disclaimer: This webinar is for professional educational purposes only. Currently there are no pharmaceutical or natural medicines approved by the FDA to specifically treat COVID-19.

EVEXIA TESTING AND NUTRACEUTICAL RECOMMENDATIONS FOR BUILDING AND SUPPORTING A STRONG IMMUNE SYSTEM

Recommended Evexia Panels

2020 Complete Wellness Panel
    • Apolipoprotein B
    • Bilirubin, Direct
    • Complete Blood Count (CBC) With Differential
    • Comprehensive Metabolic Panel (CMP-14)
    • Cortisol
    • C-Reactive Protein (CRP), High Sensitivity
    • Dehydroepiandrosterone (DHEA) Sulfate
    • Ferritin + Iron + Total Iron-binding Capacity (TIBC)
    • Fibrinogen Activity (Factor I Activity)
    • Gamma-Glutamyl Transferase (GGT)
    • Hemoglobin (Hb) A1c With eAG
    • Homocyst(e)ine
    • Insulin
    • Lactic Acid Dehydrogenase (LD/LDH)
    • Lipid Panel + VLDL + TC/HDL Ratio + LDL/HDL Ratio + CHD Risk
    • Lipoprotein(a)
    • Magnesium
    • Phosphorus
    • Thyroid Profile II, Comprehensive (FTI; T3 Uptake; TSH; T4; T3)
    • Uric Acid
    • Vitamin D, 25-Hydroxy
2020 Comprehensive Wellness Panel
    • Apolipoprotein B
    • Bilirubin, Direct
    • Coenzyme Q10, Total (CoQ10)
    • Complete Blood Count (CBC) With Differential
    • Comprehensive Metabolic Panel (CMP-14)
    • Cortisol
    • C-Reactive Protein (CRP), High Sensitivity
    • Deaminated Gliadin Antibodies, IgA & IgG
    • Dehydroepiandrosterone (DHEA) Sulfate
    • Estradiol (E2)
    • F2-Isoprostane/Creatinine Ratio
    • Ferritin + Iron + Total Iron-binding Capacity (TIBC)
    • Fibrinogen Activity (Factor I Activity)
    • Folate, RBC
    • Gamma-Glutamyl Transferase (GGT)
    • Hemoglobin (Hb) A1c With eAG
    • Homocyst(e)ine
    • Insulin
    • Iodine, Serum or Plasma
    • Lactic Acid Dehydrogenase (LD/LDH)
    • Lipid Panel + VLDL + TC/HDL Ratio + LDL/HDL Ratio + CHD Risk
    • Lipoprotein(a)
    • Magnesium
    • Magnesium, RBC
    • Omega 3 and 6 Fatty Acids
    • Phosphorus
    • Testosterone Profile (Bioactive + Total), LC/MS-MS
    • Thyroid Profile II, Comprehensive (FTI; T3 Uptake; TSH; T4; T3)
    • Uric Acid
    • Urinalysis, Complete with Microscopic Examination
    • Vitamin B12 (Cobalamin)
    • Vitamin D, 25-Hydroxy
    • Zinc, RBC

Recommended Individual Tests

  • Complete Blood Count (CBC) With Differential
  • Comprehensive Metabolic Panel (CMP-14)
  • Cortisol
  • Eosinophil Cationic Protein (ECP) / Ribonuclease 3
  • F2-Isoprostane
  • Glutathione
  • Immunoglobulins, Quantitative, IgA, IgG, IgM
  • Influenza A and B Antibodies
  • Interleukin-02 (IL-2)
  • Mannose-binding Lectin (MBL)
  • Myeloperoxidase (MPO)
  • Natural Killer Cell and Activated T-Cell Profile/IL-2r
  • Neopterin, Urin

 

  • Respiratory Pathogen Profile, Comprehensive, PCR
  • Tumor Necrosis Factor-α
  • Vitamin A (Retinol)
  • Vitamin C (Ascorbic Acid)
  • Vitamin C (With Dilution)
  • Zinc, RBC

Recommended Specialty Tests

  • GDX- ImmunoGenomic Profile
  • GDX- ION Profile
  • GDX- NutrEval
  • GDX- ONE (Optimal Nutritional Evaluation) FMV
  • GDX- Oxidative Stress Analysis 2.0
  • Spectracell- Micronutrient Test

Recommended Evexia Nutraceuticals and Supplements

Currently there are no pharmaceutical or natural medicines approved by the FDA to specifically treat COVID-19​.

Immune Essentials Plus

More information >>

Silver Max

More information >>

Zinc Max

More information >>

Essential Protein BEEF Plus

More information >>

C+Flavinoids

More information >>

Multi Complex Plus

More information >>

Max Antiox Complete

More information >>

S-Acetyl Glutathione
Complete

More information >>

Monolaurin or Monolauric Acid (MLA)​

More information

Monolaurin has demonstrated antibacterial, antiviral, and antimicrobial properties. Studies have also shown that Monolauric Acid can disintegrate the protective viral envelope, thereby preventing it from attaching and entering host cells, and ultimately kill the virus. MLA can also help the immune system recognize a pathogen by increasing immunogenicity creating an additional antigenic epitope that can be recognized by T-helper cells. This dramatically improves the immune response time and allows for a quicker resolution of infection.

LiveZilla Live Chat Software